latest news releases from the newsroom
BioMar -- Contemplated Sale of Shares by Norsk Hydro
OSLO, Norway, Oct. 18, 2005 (PRIMEZONE) -- Norsk Hydro ("Hydro") (NYSE:NHY) (Oslo:NHY) has decided to evaluate a potential sale of all or some of Hydro's shares in BioMar Holding A/S ("BioMar"). Hydro has in this respect retained a financial advisor to advice on, and execute, a potential sale. Hydro currently owns 7,569,990 shares in BioMar, representing 68.82% of total number of shares outstanding.
Occidental Petroleum Corp.
Occidental to Hold Earnings Conference Call
LOS ANGELES, Oct. 18, 2005 (PRIMEZONE) -- Occidental Petroleum Corporation (NYSE:OXY) will hold a conference call on Monday, October 31, 2005, following the release of its third-quarter 2005 financial results. The conference call, which will begin at 11:30 a.m. EDT, may be accessed by calling 1-888-873-8496. The conference call also can be heard live on the company's website, www.oxy.com. All remarks made during the conference call will be current at the time of the call and will not be updated to reflect subsequent material developments. Third-quarter financial results will be available through the Investor Relations section of the company's website concurrent with the SEC filing. An archived edition of the conference call also will be available on the website within several hours after the call is completed.
ZipForm and Auto-RE Partner to Automate Real Estate Business Processes
CLINTON TOWNSHIP, Mich., Oct. 18, 2005 (PRIMEZONE) -- ZipForm's electronic forms software already saves users time and helps reduce data-entry errors by allowing data to be entered once and used multiple times, in all documents associated with a transaction. Now, with a partnership with Auto-RE(tm), that transaction data can flow even further.
Dr. Rath Education Services USA, BV
Nutrient Combination Stops Cancer Metastasis in Mice
SANTA CLARA, Calif., Oct. 18, 2005 (PRIMEZONE) -- At the 10th World Congress on Advances in Oncology and 8th International Symposium on Molecular Medicine, held October 13-15, 2005 in Crete, Greece, scientists with the Dr. Rath Research Institute revealed a new study that shows cancer metastasis can be stopped in mice using a combination of nutrients.
XsunX Developing New Nano-Crystalline Opaque Solar Cell
ALISO VIEJO, Calif., Oct. 18, 2005 (PRIMEZONE) -- XsunX, Inc. (OTCBB:XSNX), developer of Power Glass(tm) -- an innovative solar technology that allows glass windows to produce electricity from the power of the sun -- announced that it has expanded its business opportunities to include the product development of a new opaque solar cell device. This unique four-terminal solar cell design uses a combination of thin film transparent cell technology, derived from the company's Power Glass initiative, with that of a nano-crystalline solar cell. XsunX believes that the combination of these two technologies into a single device holds a promising opportunity to deliver low cost, high efficiency, flexible, and light weight solar cells providing performance characteristics commonly found only in various forms of expensive crystalline wafer technologies.
UCB: Phase III Study Shows CIMZIA is an Effective and Well-Tolerated Treatment for Crohn's Disease
BRUSSELS, Belgium and COPENHAGEN, Denmark, Oct. 18, 2005 (PRIMEZONE) -- UCB announced today at the United European Gastroenterology Week the detailed Phase III study results (PRECiSE 2) for CIMZIA(TM) (certolizumab pegol, CDP870) in the treatment of Crohn's disease. The results of the PRECiSE 2 study show that the anti-TNF CIMZIA was efficacious at decreasing or controlling the signs and symptoms of Crohn's disease. UCB's anti-TNF treatment, which is administered via subcutaneous injection, was also shown to be well-tolerated.(1) A regulatory submission for the treatment of Crohn's disease is scheduled to be filed for CIMZIA in both the U.S. and Europe during the first quarter of 2006.
Biogenerics Announces Financing Plan for the Hydroslotter Roll Out
TORONTO, Oct. 18, 2005 (PRIMEZONE) -- Biogenerics Limited (Pink Sheets:BIGN): The company is pleased to announce that it has secured an agreement with an institutional investor Royal Petroleum. Royal Petroleum purchases and finances producing oil and gas wells. Biogenerics has financing in place for hydroslotting at 8.5% interest as needed and secured by our current production.